
Results
423
Companies which are more than 50% undervalued based on analyst price target.
423 companies
Alnylam Pharmaceuticals
Market Cap: US$30.0b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$227.12
7D
5.1%
1Y
-48.7%
Insmed
Market Cap: US$28.9b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$126.33
7D
-4.7%
1Y
-1.1%
Summit Therapeutics
Market Cap: US$12.1b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$15.10
7D
11.6%
1Y
-43.8%
Praxis Precision Medicines
Market Cap: US$10.8b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$368.46
7D
-0.5%
1Y
672.5%
Ionis Pharmaceuticals
Market Cap: US$9.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$55.87
7D
2.5%
1Y
30.4%
Vaxcyte
Market Cap: US$8.9b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$58.86
7D
-0.05%
1Y
87.3%
ImmunityBio
Market Cap: US$8.2b
A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
IBRX
US$7.65
7D
4.5%
1Y
182.3%
Definium Therapeutics
Market Cap: US$5.7b
A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.
DFTX
US$43.90
7D
-4.9%
1Y
351.6%
CRISPR Therapeutics
Market Cap: US$5.2b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$53.99
7D
2.9%
1Y
-5.8%
Dyne Therapeutics
Market Cap: US$4.9b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$25.96
7D
0.3%
1Y
107.7%
Celcuity
Market Cap: US$4.5b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$86.60
7D
-7.1%
1Y
66.9%
Tango Therapeutics
Market Cap: US$4.3b
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$25.65
7D
-11.6%
1Y
270.7%
Legend Biotech
Market Cap: US$4.0b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$20.27
7D
5.1%
1Y
-46.2%
Viking Therapeutics
Market Cap: US$4.0b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$32.94
7D
-1.1%
1Y
-18.1%
Structure Therapeutics
Market Cap: US$3.7b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$53.91
7D
6.7%
1Y
181.4%
NewAmsterdam Pharma
Market Cap: US$3.3b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$27.83
7D
1.5%
1Y
8.0%
Alumis
Market Cap: US$3.3b
A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
ALMS
US$24.41
7D
-12.2%
1Y
456.0%
AbCellera Biologics
Market Cap: US$3.2b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$10.97
7D
68.0%
1Y
143.8%
BioCryst Pharmaceuticals
Market Cap: US$2.7b
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BCRX
US$9.81
7D
5.5%
1Y
16.1%
Beam Therapeutics
Market Cap: US$2.7b
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
BEAM
US$26.51
7D
-2.7%
1Y
50.4%
Ultragenyx Pharmaceutical
Market Cap: US$2.6b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
RARE
US$26.38
7D
2.2%
1Y
-9.1%
Viridian Therapeutics
Market Cap: US$2.6b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$21.99
7D
-2.3%
1Y
19.3%
Nektar Therapeutics
Market Cap: US$2.6b
A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
NKTR
US$76.16
7D
3.7%
1Y
185.4%
Trevi Therapeutics
Market Cap: US$2.5b
A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$18.14
7D
-1.9%
1Y
142.2%
Precigen
Market Cap: US$2.5b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$6.47
7D
-6.4%
1Y
249.7%
Kailera Therapeutics
Market Cap: US$2.4b
Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
KLRA
US$17.97
7D
-4.8%
1Y
n/a
Mineralys Therapeutics
Market Cap: US$2.4b
A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$26.09
7D
-3.3%
1Y
84.6%
SELLAS Life Sciences Group
Market Cap: US$2.4b
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$12.36
7D
5.6%
1Y
697.4%
Nuvation Bio
Market Cap: US$2.3b
A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
NUVB
US$6.10
7D
-0.2%
1Y
121.0%
Ocular Therapeutix
Market Cap: US$2.2b
A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
OCUL
US$10.10
7D
15.6%
1Y
-20.2%
ADMA Biologics
Market Cap: US$2.2b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.41
7D
-6.5%
1Y
-44.5%
Vera Therapeutics
Market Cap: US$2.2b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$29.99
7D
-1.2%
1Y
36.5%
Biohaven
Market Cap: US$2.2b
A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
BHVN
US$14.85
7D
3.0%
1Y
4.4%
Stoke Therapeutics
Market Cap: US$2.1b
Engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$31.30
7D
-2.0%
1Y
82.3%
Taysha Gene Therapies
Market Cap: US$2.1b
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
TSHA
US$6.00
7D
-5.4%
1Y
104.1%
Kardigan
Market Cap: US$2.0b
Operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
KARD
US$21.78
7D
7.6%
1Y
n/a